Strong Treatment Response and High Maintenance Rates of Clozapine in Childhood-Onset Schizophrenia

Journal of Child and Adolescent Psychopharmacology
Lauren I KasoffJudith L Rapoport

Abstract

Childhood-onset schizophrenia (COS) is a rare but severe form of the disorder, which is often treatment refractory. Short-term studies have indicated a greater differential efficacy, evident through effect sizes, favoring clozapine over other agents in alleviating negative symptoms in COS patients compared with adult-onset patients (AOS). There have been no data for COS patients on long-term compliance with clozapine treatment. Therefore, we wanted to know, over a span of up to 24 years, how many of our COS cohort had remained on clozapine for at least 2 years. We review short-term treatment data and present updated long-term data on compliance and functioning for our patients. We present the results for long-term medication maintenance over a 24 year observation period for our cohort of 131 patients. Of this cohort, 91.6% (120) were available for follow-up information from either in-person or telephone contact with the patient and/or family members. We defined clozapine compliance as ≥2 years receiving this medication and doing well. We were able to contact 120 of the 131 patients. In spite of the additional cost and inconvenience of regular blood monitoring, 87 patients (72.5%, 87/120) adhered to long-term clozapine maintenan...Continue Reading

Associated Clinical Trials

References

Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Nov 1, 1983·Archives of General Psychiatry·D ShafferS Aluwahlia
Jan 1, 1994·Schizophrenia Bulletin·C T GordonK E Albus
Jun 1, 1994·Journal of the American Academy of Child and Adolescent Psychiatry·K McKennaJ L Rapoport
Jul 15, 1993·The New England Journal of Medicine·J M AlvirJ A Schaaf
Mar 1, 1996·The American Journal of Psychiatry·L K JacobsenJ L Rapoport
Jul 1, 1996·Archives of General Psychiatry·J A FrazierJ L Rapoport
Dec 1, 1996·Archives of General Psychiatry·S KumraJ L Rapoport
Oct 24, 1997·Archives of General Psychiatry·T P ZahnJ L Rapoport
Feb 13, 2001·Biological Psychiatry·G D TollefsonUNKNOWN Lilly Resistant Schizophrenia Study Group
Oct 26, 2001·Psychiatry Research·J G LevittJ T McCracken
Jan 25, 2003·Journal of Clinical Psychopharmacology·Jean A FrazierJudith L Rapoport
Mar 4, 2003·The American Journal of Psychiatry·Rob NicolsonJudith L Rapoport
Sep 1, 1963·Archives of General Psychiatry·W E BUNNEY, D A HAMBURG
Nov 19, 2003·Journal of Clinical Psychopharmacology·Robert R ConleyWilliam T Carpenter
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Istvan BitterUNKNOWN Olanzapine HGCK Study Group
Apr 20, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Péter Gaszner, Zoltán Makkos
Jan 18, 2005·Schizophrenia Research·Alexandra SpornJudith L Rapoport
Dec 3, 2005·Child and Adolescent Psychiatric Clinics of North America·Harvey N KranzlerSanjiv Kumra
Jul 5, 2006·Archives of General Psychiatry·Philip ShawJudith L Rapoport
Feb 23, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Robert L FindlingChristopher J Kratochvil
Sep 22, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Alexandra L SpornNitin Gogtay
Jan 18, 2008·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Luke T Curtis, Kalpana Patel
Mar 24, 2009·Current Psychiatry Reports·Anjené M Addington, Judith L Rapoport
Apr 11, 2012·Molecular Psychiatry·J L RapoportN Gogtay
Mar 15, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Carolina SchneiderSophia Frangou

❮ Previous
Next ❯

Citations

May 22, 2018·American Journal of Therapeutics·Ahmed NaguyBader Khraibut
Oct 26, 2018·Journal of Child and Adolescent Psychopharmacology·Laura M SteinauerJennifer L Vande Voort
Dec 6, 2018·International Journal of Molecular Sciences·Anke HoffmannDietmar Spengler
Dec 20, 2017·Journal of Clinical Psychopharmacology·Amitkumar ChouguleP S V N Sharma
Jul 8, 2020·Journal of Child and Adolescent Psychopharmacology·Jerome H TaylorMichael H Bloch
May 15, 2019·American Journal of Therapeutics·Vivekananda RachamalluManish Aligeti
May 16, 2017·Acta Psychiatrica Scandinavica·C J BachmannD Taylor
Mar 19, 2021·Journal of Clinical Psychopharmacology·Louis-David LeclercMarc-André Roy
Jul 21, 2021·Journal of Child and Adolescent Psychopharmacology·Gul KaracetinYesim Saglam

❮ Previous
Next ❯

Methods Mentioned

BETA
blood draws

Software Mentioned

Optimise

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.